What is Scisco Genetics?
Scisco Genetics operates at the intersection of biotechnology and consumer wellness, providing sophisticated genetic testing and analytical services. The company's core value proposition lies in its ability to translate complex genomic data into actionable health insights for a diverse clientele, ranging from fitness enthusiasts to medical practitioners. By utilizing advanced sequencing technology, Scisco Genetics empowers users to make data-driven decisions regarding their long-term health and wellness strategies.
The company occupies a critical niche in the precision medicine market, where the demand for personalized health information continues to surge. Through its commitment to scientific rigor and user-centric design, Scisco Genetics has established itself as a reliable partner for individuals and professionals seeking to optimize health outcomes through genetic intelligence.
How much funding has Scisco Genetics raised?
Scisco Genetics has raised a total of $611K across 4 funding rounds:
Debt
$111K
Multiple Rounds
$500K
Debt (2021): $111K with participation from PPP
Debt (2025): $297K led by Bank of America
Debt (2025): $75K supported by WSFS Bank
Debt (2025): $128K featuring Bank of America
Key Investors in Scisco Genetics
Bank of America
A global financial services leader providing comprehensive banking and capital solutions to support large-scale corporate growth and strategic debt financing.
WSFS Bank
A prominent regional financial institution focused on delivering specialized commercial banking services and credit facilities to growing enterprises.
PPP
Public-Private Partnership
What's next for Scisco Genetics?
With the recent capital injection, Scisco Genetics is poised to prioritize the scaling of its laboratory operations and the refinement of its diagnostic algorithms. The strategic focus will likely shift toward deepening market penetration among medical professionals, thereby bridging the gap between consumer-facing wellness tools and clinical-grade genetic diagnostics. Furthermore, the company is expected to invest in research and development to broaden its service portfolio, ensuring it remains at the forefront of the rapidly evolving genomics industry.
The involvement of major financial institutions suggests a stable path forward, with the company likely focusing on operational efficiency and sustainable growth. As Scisco Genetics continues to integrate its services into broader health ecosystems, the firm is well-positioned to capitalize on the increasing global emphasis on preventative and personalized healthcare solutions.
